Oragenics Inc. Files 8-K Report
Ticker: OGEN · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1174940
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: ORGN
TL;DR
ORGN filed an 8-K, mostly procedural stuff, check filings for details.
AI Summary
On October 15, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Oragenics, Inc. is providing updated disclosures and financial information to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and financial status.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that inherently increases risk.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- October 15, 2024 (date) — Date of earliest event reported
- 1990 Main Street Suite 750 Sarasota, FL 34236 (address) — Principal executive offices
- 813 - 286-7900 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Oragenics, Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is October 15, 2024.
What is the principal executive office address for Oragenics, Inc.?
The principal executive office address is 1990 Main Street Suite 750, Sarasota, FL 34236.
What is the telephone number for Oragenics, Inc.?
The registrant's telephone number is 813-286-7900.
What is the state of incorporation for Oragenics, Inc.?
Oragenics, Inc. is incorporated in Florida (FL).
Filing Stats: 661 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-10-16 10:30:17
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 735KB
- ex99-1_002.jpg (GRAPHIC) — 1771KB
- ex99-1_003.jpg (GRAPHIC) — 1143KB
- ex99-1_004.jpg (GRAPHIC) — 1016KB
- ex99-1_005.jpg (GRAPHIC) — 1070KB
- ex99-1_006.jpg (GRAPHIC) — 1010KB
- ex99-1_007.jpg (GRAPHIC) — 1074KB
- ex99-1_008.jpg (GRAPHIC) — 1009KB
- ex99-1_009.jpg (GRAPHIC) — 1094KB
- ex99-1_010.jpg (GRAPHIC) — 1275KB
- ex99-1_011.jpg (GRAPHIC) — 909KB
- ex99-1_012.jpg (GRAPHIC) — 776KB
- ex99-1_013.jpg (GRAPHIC) — 1013KB
- ex99-1_014.jpg (GRAPHIC) — 1290KB
- ex99-1_015.jpg (GRAPHIC) — 987KB
- ex99-1_016.jpg (GRAPHIC) — 951KB
- 0001493152-24-041255.txt ( ) — 23778KB
- ogen-20241015.xsd (EX-101.SCH) — 3KB
- ogen-20241015_lab.xml (EX-101.LAB) — 33KB
- ogen-20241015_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this October 16, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer